/PRNewswire/ Over the weekend at its quarterly meeting, the national board of directors for the American Liver Foundation (ALF) announced the election of a.
E-Mail
IMAGE: Human liver cell lines (green, with blue nuclei) infected with HBV express an HBV protein (in red) in this image captured by immunofluorescence microscopy. view more
Credit: Image by Stephanie Maya, Princeton University
Researchers at Princeton have determined how five cellular proteins contribute to an essential step in the life cycle of hepatitis B virus (HBV). The article describing these findings appeared March 11, 2021 in the journal
Nature Communications.
Viruses have been with us, shaping our lives, societies and economies for millennia. While some viruses rapidly explode onto the world stage, others smolder in our communities for decades, shattering lives but making few headlines. Hepatitis B virus hasn t caused any nationwide lockdowns or stock market crashes because it is slow to spread from person to person and is rarely immediately fatal. It is nonetheless incredibly damaging because it can establish lifelong chronic infection with profoun
Alentis Therapeutics: Alentis Founder Receives Prestigious French Academy of Science Award
Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Prof. Thomas Baumert, its founder and world-leading authority in the field, has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201222005253/en/
Professor Thomas Baumert, founder of Alentis Therapeutics. Copyright Alentis Therapeutics
Said Prof. Thomas Baumert: It s a great honor and a mark of recognition for my team, my colleagues and collaborators, some 50 in all. Now we are going to have to redouble our efforts, with a view to bringing our research to patients so they can truly benefit.
Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Prof. Thomas Baumert, its founder and world-leading authority in the field, has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer.
Professor Thomas Baumert, founder of Alentis Therapeutics. Copyright Alentis Therapeutics
Said Prof. Thomas Baumert: “It’s a great honor and a mark of recognition for my team, my colleagues and collaborators, some 50 in all. Now we are going to have to redouble our efforts, with a view to bringing our research to patients so they can truly benefit.”
Bucks County Courier Times
DOYLESTOWN Hepatitis B Foundation co-founders Joan and Timothy Block were presented with the inaugural Distinguished Advocacy Service Award during the annual meeting of the American Association for the Study of Liver Diseases, or AASLD.
The Blocks were recognized for their efforts to raise awareness and prioritization of hepatitis B, and to ensure that the 2 million people living with hepatitis B in the U.S. have unhindered access to screening, appropriate medical care and treatment.
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.
The Hepatitis B Foundation, headquartered in the Pennsylvania Biotechnology Center in Buckingham, is a nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide.